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Abstract: Aerobic metabolism of mammalian cells leads to the generation of reactive oxygen species (ROS).  To 
cope with this toxicity, evolution provided cells with effective antioxidant systems like glutathione. Current 
anticancer therapies focus on the cancer dependence on oncogenes and non-oncogenes. Tumors trigger 
mechanisms to circumvent the oncogenic stress and to escape cell death. In this context we have studied 2-
phenylethinesulfoxamine (PES), which disables the cell protective mechanisms to confront the proteotoxicity of 
damaged and unfolded proteins. Proteotoxic stress is increased in tumor cells, thus providing an explanation for 
the anticancer selectivity of PES. In addition, we have found that PES induces a severe oxidative stress and the 
activation of p53. The reduction of the cell content in glutathione by means of L-buthionine-sulfoximine (BSO) 
synergizes with PES. In conclusion, we have found that ROS constitutes a central element in a series of positive 
feed-back loops in the cell. ROS, p53, proteotoxicity, autophagy and mitochondrial dynamics are interconnected 
with the mechanisms leading to cell death, either apoptotic or necrotic. This network of interactions provides 
multiple targets for drug discovery and development in cancer. 
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BACKGROUND ON REACTIVE OXYGEN SPECIES 
Free radicals are a concept of chemistry. A free radical is defined as an atom or molecule characterized 
by having unpaired valence electrons. Therefore it becomes a high-reactive entity with potential to interact and 
disrupt biological molecules, either the simplest (carbohydrates and lipids) or the most complex ones (nucleic 
acids and proteins). Free radicals are present in our environment as the result of chemical processes or ionizing 
radiation, for instance as a by-product of industrial activity. Alternatively, they can be produced in vivo as the 
result of the cellular metabolism.  
Free radicals derived from oxygen are the most prominent in the cellular context.  They are generated 
by the progressive reduction of molecular oxygen (O2) to finally yield H2O. In Fig. (1A), we show a classical 
scheme of this process plus the enzymes and reactions involved in vivo [1].  The ionic nature of superoxide anion 
(O2•–) confers cell membrane impermeability to this entity. It is neutralized and converted to hydrogen peroxide 
by the superoxide dismutase enzymes (SOD). The hydroxyl radical (OH•) is highly reactive and, therefore, 
harmful for biological molecules. It is generated by the Fenton and Haber-Weiss reactions that require the 
participation of transition metals, frequently iron (Fe) in a biological context. Finally, hydrogen peroxide (H2O2) 
is no strictly a free radical. However, its oxidant capacity added to its efficiency in crossing biological 
membranes define a highly toxic profile for H2O2. In addition H2O2 becomes the precursor of OH• radical via the 
Fenton and Haber-Weiss reactions mentioned above. These three molecules are collectively termed reactive 
oxygen species (ROS). The mitochondrial process of oxidative phosphorylation (OXPHOS) is the main source 
of ROS in the cells. The ATP yield of the OXPHOS process is greatly advantageous to eukaryotic cells but it 
implies intracellular toxicity by the generation of ROS. This ambivalent role of oxygen in life has been 
traditionally referred to as the “oxygen paradox”. However, there are other locations where ROS can be 
generated. For example, there is a subtle and regulated release of ROS at the cellular membranes mediated by 
NADPH oxidases (Nox family of proteins) and involved in cell signalling [2]. 
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Massive ROS generation is harmful for the cells. ROS oxidise and disrupt essential molecules like 
lipids, proteins and nucleic acids. Consequently cells counterbalance ROS by means of detoxifying enzymes or 
molecules with chemical reducing activity [1]. As shown in Fig. (1A), H2O2 is the substrate of catalase (CAT), 
peroxiredoxins (PR) and glutathione peroxidase (GPx). Vitamin E (VitE) and C (VitC) are molecules with 
reducing properties in specific intracellular compartments, lipophilic for VitE and hydrophilic for VitC (Fig. 1B). 
The most relevant antioxidant molecule inside the cell is glutathione and this relevancy is even higher inside the 
mitochondrial matrix [3]. Because of its high intracellular concentration, reduced glutathione (GSH) determines 
the intracellular reduction potential. Once oxidised, GSH becomes glutathione disulphide (GSSG). Glutathione 
reductase (GR) is the enzyme that regenerates GSH. This reduction is coupled to the oxidation of NADPH (Fig. 
1B). GSH is a peptide composed of three amino acids, glutamate, cysteine and glycine. The enzyme glutamate-
cysteine ligase (GCL), previously named γ-glutamylcisteine synthetase, catalyses the first step in the synthesis of 
GSH. Then glutathione synthetase catalyses the binding of glycine and, as a result, glutathione (γ-glutamyl-
cisteinylglycine) is generated. Glutathione (GSH) participates in many intracellular processes (Fig. 1B). For 
instance it reduces the thiol groups of the oxidised proteins, the VitC and, indirectly, the VitE. GSH associates to 
GPx to transform H2O2 into H2O. GSH can be conjugated to drugs, thus defining a specific type of phase II 
reactions in the metabolism of drugs. Finally, it can also be conjugated to proteins, thus becoming the post-
translational modification termed glutathionylation [3]. In a healthy cell, ROS and antioxidant resources are in a 
homeostatic equilibrium, the imbalance leads to oxidative damage and, eventually, to cell death. The loss of the 
homeostatic balance is designated as oxidative stress. 
Fig. (1). (A) Graphical summary of the chemical process of O2 reduction to H2O. The reaction catalysed by 
superoxide dismutase enzymes (SOD) is shown. The generation of hydroxyl radical (OH•) by Haber-Weis and 
Fenton reactions is indicated. Finally, catalase (CAT), peroxiredoxin (PR) and glutathione peroxidase (GPx) are 
the enzymatic activities devoted to neutralize hydrogen peroxide (H2O2) inside the cells. (B) Scheme of the 
glutathione (GSH) redox cycle and its coupling to other redox cycles and conjugation reactions inside the cell. 
The ox- prefix denotes the oxidized form. Glutathione reductase (GR), glutathione peroxidase (GPx), and the 
superfamily of glutathione transferases (GT) are indicated close to the reactions they catalyse. 
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CURRENT STRATEGIES IN CANCER TREATMENT 
The beginning of the 21st century coincided with the commercialization of Imatinib mesylate 
(Gleevec®). Imatinib is an inhibitor of ABL tyrosine kinase. The function of ABL is to promote the survival of 
cells subjected to genotoxic stress. The reciprocal translocation that generates the Philadelphia chromosome is 
characteristic of chronic myeloid leukemia (CML). The translocation produces a fusion protein (BCR-ABL) and 
an abnormal increase of ABL activity. The cells of CML become dependent on ABL activity to circumvent cell 
death by apoptosis. Therefore, Imatinib triggers apoptosis of CML cells and an impressive clinical outcome in 
CML patients [4,5]. Moreover, the specificity of Imatinib for ABL is not absolute. Imatinib also inhibits the c-
KIT kinase that is relevant to the development of the gastrointestinal stromal tumor (GIST). Therefore, Imatinib 
has also become a successful treatment for GIST [6]. This type of therapeutic strategy has been designated as 
cancer specific, because the drug targets one or a few types of tumor exclusively, as exemplified by Imatinib. 
This strategy has also been labelled as personalised therapy of cancer because, for instance, among the patients 
with gastric cancer, only those with GIST are responsive to Imatinib. The common trait underlying this strategy is 
the dependence on one specific oncogene of one specific cancer cell (Fig. 2). This evokes the phenomenon of 
addiction and, consequently, the “oncogene addiction” allegory has met some success to term this concept. 
Oncogenesis implies many disruptions in the cell homeostasis that incline cells to die, frequently via apoptosis. 
This cell predisposition uncovers a cellular stress that can be referred to as oncogenic stress. Therefore, the 
recruitment of antiapoptotic and other pro-survival mechanisms are needed for the progression and success of the 
oncogenic process. Actually, these pro-survival mechanisms become a druggable weakness, what has lead to the 
metaphor that “Achilles heels” exist in cancer cells.  
Trastuzumab, a humanized monoclonal antibody against HER protein in breast cancer, Gefitinib and 
Erlotinib in those non-small cell lung cancers (NSCLC) with mutated EGF receptor, or Crizotinib for NSCLC 
with the fusion protein EML4-ALK, are examples of drugs directed to the “Achilles heel” of specific types of 
tumors, in clinical use presently [7]. Still in an experimental phase, the possibility of a combined drug therapy 
emerges. For instance, the synergistic association of ABT-737 and Roscovitine or its R-enantiomer (Seleciclib) 
[8,9]. Many tumor cells are dependent on the antiapoptotic Bcl-2 gene to circumvent the oncogenic stress. This 
stress can be caused by the increase of some of the BH3-only proteins, which are pro-apoptotic and antagonistic 
of Bcl-2 (Fig. 2).  In this context, specific inhibitors of Bcl-2 like ABT-737 are of great interest. However, it has 
been found that cells become resistant to ABT-737 by overexpressing Mcl-1, a short-lived, antiapoptotic protein 
of the Bcl-2 family. Mcl-1 is not inhibited by ABT-737. In this context, the inhibition of CDK9 and the 
subsequent transcriptional elongation phenomenon by Roscovitine/Seleciclib promotes an early and fast decay of 
the Mcl-1 protein [10]. Therefore, ABT-737 and Roscovitine/Seleciclib can be successfully combined to kill 
cancer cells selectively (Fig. 2). 
Stressed cells rely on homeostatic mechanisms such as the chaperone activity of heat shock proteins 
(HSP). The same holds true for tumors that are naturally exposed to oncogenic stress. These homeostatic 
mechanisms are not intrinsically oncogenic but a response to the oncogenic stress and, therefore, the concept of 
non-oncogene dependence or “non-oncogene addiction” of cancer can be proposed (Fig. 2). The best examples of 
drugs following this strategy are the inhibitors of HSP70 (PES) and HSP90 (Geldanamycin). HSP70 and 90 
prevent misfolding and aggregation of proteins due to their chaperone activity. In addition, HSP70 is involved in 
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the autophagic clearance of proteins either misfolded or aggregated. PES (2-phenylethinesulfonamine) has proven 
to be quite selective at killing cancer cells by promoting proteotoxic stress and causing a necrotic type of cell 
death [11,12]. This fact has stimulated the research in this category of innovative drugs [13–15].  
There are other cellular phenomena that can be harnessed to fight cancer. Cells can be induced to 
terminally differentiate or to enter senescence. Both processes imply a cytostatic effect, i.e. cell quiescence and 
the stop of the cancer growth. Nevertheless killing cancer cells, i.e. a cytocidal effect, seems the most direct 
approach to achieve cancer regression. There are different types of cell death that are periodically classified and 
catalogued [16]. In brief, type 1 is apoptosis, which morphological and molecular definition is precise. Type 2 is 
autophagic cell death, which is considered a misnomer. Autophagy is frequently found in dying cells, but it is 
rarely involved in causing the cell demise. On the contrary, autophagy is essentially helping the cells to get rid of 
protein aggregates, damaged organelles and subsequent ROS production. Type 3 is necrosis, which is 
characterized by membrane disruption and the spillage of the cell content. Because of this spillage, necrosis has 
the ability to promote immunity, strong inflammatory responses and tissue disruption. This fact has traditionally 
been considered negative when compared to the silent, self-contained apoptotic process. However, apoptosis is 
not so self-contained. Some apoptotic cells expose Calreticulin at the cell surface and secrete ATP and HMGB1 
protein. These events are highly immunogenic and have proved to be crucial for succeeding in causing tumor 
regression with apoptosis-inducing agents. This is the case of Doxorubicin, Cyclophosphamide, Bortezomib or 
γ-irradiation [17,18]. Accordingly, the interest of the agents that induce necrotic cell death should be 
reconsidered.  
 
 
Fig. (2). Scheme illustrating how the oncogenic process sets the cells in a state of stress that predisposes to cell 
death, for example by an elevated ROS content and oxidative stress. To avoid their demise, cells follow two 
different strategies: (1) Oncogene dependence. (2) Non-oncogene dependence. This allows the identification of 
targets for drug development. This approach is supported by the success of drugs such as Imatinib, Crizotinib 
and other, presently and routinely used in patient treatment. 
  
OXIDATIVE STRESS, p53 AND CANCER THERAPEUTICS 
In Fig. (2), elevated ROS are part of the cellular stress derived from oncogenesis. In other words, 
oxidative stress becomes part of the oncogenic stress of a cell. Is this true for all cancer cells? Is this an “Achilles 
heel” to be exploited in the treatment of a few, many or most tumors? The answers are subject to controversy. For 
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instance, inactivating mutations and deletions of p53 are the most common event in human cancer [19,20]. As a 
tumor suppressor, p53 senses many different stresses of the cell and triggers a plethora of responses, ranging from 
cell cycle stop to apoptotic cell death [21]. In spite of being a transcription factor, p53 can activate either 
transcriptional or non-transcriptional responses [22]. For instance, its translocation to mitochondria to directly 
activate the mitochondrial outer membrane permeabilisation (MOMP) and apoptosis [23]. The search for a drug 
with the ability to block this translocation was the aim of the research that led to the discovery of PES. This fact 
explains the alternative designation of PES as pifithrin-µ [24]. Among the genes regulated by p53 is TIGAR 
(TP53-induced glycolysis and apoptosis regulator). This gene connects p53 and the regulation of glucose 
metabolism and ROS. TIGAR promotes the redirection of glucose towards the pentose phosphate shunt and, 
therefore, increases the production of reduced NADPH [25]. Consistently, a reduced function of TIGAR provides 
a good explanation for the increased ROS phenotype of tumor cells with a defective function of p53. In this 
context, the ROS threshold hypothesis for cancer therapy was formulated. In brief, tumor cells suffer from 
oxidative stress to a greater extent than non-tumor ones and, as a consequence, they are closer to the threshold of 
cell death induction by ROS. Accordingly, the therapeutic agents with the ability to increase ROS will 
preferentially harm the tumor cells [26]. Indeed, broadly-use therapies such as irradiation and anthracyclines act, 
in part, by increasing ROS in cancer cells. Particularly, the glycopeptide bleomycin has a mechanism of action 
directly based on ROS generation and subsequent DNA damage and fragmentation. The recently approved 
arsenic trioxide is also a direct producer of ROS in cancer cells. Regarding cancer therapy, several potential new 
drugs with the ability to promote oxidative stress have reached clinical phases of development (Table 1). 
 
Table 1. ROS modulating agents undergoing clinical trials in oncology [27] 
Agent  Mode of action 
NOV-002 A form of oxidised glutathione (GSSG) that promotes intracellular GSH/GSSG 
imbalance, therefore mild oxidative stress and protein glutathionylation 
BSO  
(L-buthionine-sulfoximine) 
Inhibitor of glutamate cysteine ligase (GCL) that causes the synthesis of GSH to be 
impaired. In this inhibition context, GSH can be depleted by oxidative stress 
Canfosfamide Inhibitor of glutathione transferase (GT) activity  
Ezatiostat  hydrochloride Inhibitor of glutathione transferase (GT) activity 
Imexon Pro-oxidant molecule able to deplete cells from GSH 
Disulfiram Acetaldehyde dehydrogenase inhibitor, classical inducer of alcohol intolerance and 
pro-oxidant of GSH 
PX-12 Inhibitor of thioredoxin-1, which is overexpressed in tumors with an aggressive 
phenotype 
Dimesna Dual inhibitor of thioredoxin-1 and glutaredoxin by an ill-defined mechanism 
Motexafin gadolinium Dual inhibitor of thioredoxin reductase and ribonucleotide reductase 
Darinaparsin  Arsenic derivative 
 
None of the above mentioned compounds displays the type of anticancer specificity observed in the treatments 
with Imatinib, Crizotinib, etc. They are promising agents but behave as non-selective chemotherapeutic drugs. 
There are two important caveats concerning this therapeutic approach. First, cancer cells are heterogeneous inside 
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a tumor and, as a consequence, some cells can be far away from the lethal threshold of ROS. Second, the hypoxic 
and nutrient-poor tumor environment selects for cells with increased antioxidant capacity, i.e. elevated GSH 
content. This GSH-rich phenotype is associated with the proficiency of the cancer cells to metastasize [28]. In 
conclusion, a ROS-inducing treatment could be overtly partial and promote a more aggressive phenotype. In our 
opinion, the possibility to be specific or succeed in cancer treatment simply by increasing ROS is scarce. 
However, we are not so reluctant about the possibility to combine drugs that encompass oxidative stress, as we 
will discuss below. 
Initially observed in 1924 by Otto Warburg, the Warburg effect has lately attracted a great attention in 
oncology [29]. The effect consists in the shift of glucose metabolism from OXPHOS to lactate production in an 
oxygen-rich context. Therefore, it has been described as aerobic glycolysis. This phenomenon has provided the 
basis of an imaging technique for the diagnosis and follow-up of some tumors. This technique comprises cell 
labelling with 18F-deoxyglucose and positron emission tomography (PET) scanning. Unfortunately, to date, no 
similar applications have succeeded in the area of cancer therapy. One obvious question is how the Warburg 
effect impinges on the intracellular ROS content. The answer is that the amount of ROS generated by the 
OXPHOS process will be greatly reduced. Therefore, the Warburg effect does not help to explain why many 
cancer cells display increased ROS. Moreover, it seems to oppose the drugs that induce oxidative stress thus 
easily explaining the development of resistance. Finally, as mentioned above, it can be associated with the GSH-
rich phenotype found in metastasis. 
The relationship of p53 and ROS is paradoxical because, in opposition to TIGAR, some of the genes 
regulated by p53 generate ROS. This is the case of PIG3 (quinone oxidoreductase) and PIG6 (proline oxidase). 
Under mild p53 activation, cell cycle stop and antioxidant activity (TIGAR) would be promoted to ease the 
reparation of the damage in cellular DNA. This is consistent with the antioxidant role of the Warburg effect, that 
has been conceived as a strategy to increase the efficiency of DNA replication [29]. Conversely, under strong p53 
activation, cell death and ROS would prevail [30]. The possibility to reactivate p53 in cancer cells has 
traditionally been approached with great interest [31]. Some drugs act by counteracting some inactivating 
mutations of p53. Others, like Nutlin-3, increase p53 activity in tumors like human neuroblastoma that are usually 
characterized by a preserved p53 response [32]. Drugs acting as agonists of p53 will be expected to cause 
MOMP, apoptosis and ROS production. On the other hand, the generation of ROS will cause DNA damage and 
p53 activation. In conclusion, ROS and p53 are engaged in a positive feed-back loop. Moreover, ROS can trigger 
either MOMP and apoptosis or the opening of the mitochondrial permeability transition pore (MPTP) and 
necrosis. Both, apoptosis and necrosis are inducers of ROS. Again, this is a positive feed-back that drives the 
cells to their demise. The phenomenon of MOMP is under the control of the Bcl-2 family of proteins, 
consequently the pharmacological modulation of this event is possible by means of drugs like ABT-737, which 
neutralises some of the antiapoptotic members. Finally, in some experimental paradigms, p53 is involved in 
triggering necrotic cell death and ROS are clearly involved [33]. Taken these facts altogether, a complex net of 
mutual interactions can be considered (see Fig. 5). 
 
CELL DEATH INDUCTION BY THE ASSOCIATION OF PROTEOTOXIC AND OXIDATIVE 
STRESS  
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The screening of chemical libraries to find specific inhibitors of the translocation of p53 to mitochondria 
allowed the discovery of PES [24]. Consistently, PES protected cells from some death stimuli mediated by this 
translocation. Surprisingly, PES proved to be very lethal for neoplastic cells [11,12]. PES is a small molecule 
with chemical traits for being a highly reactive and oxidant agent (Fig. 3A). A characterization of its mode of 
action revealed its ability to block HSP70 function in vivo and as a consequence: i) the secondary inhibition of 
HSP90 and the proteasome; ii) the blockage of the chaperone-mediated type of autophagy, which results from 
HSC70 inhibition; iii) the impairment of the completion of macroautophagy (named autophagy hereafter) [12,34]. 
The implications for the cells are severe because four pivotal mechanisms to eliminate misfolded and aggregated 
proteins are lost simultaneously. We have consistently observed how multilamellar structures accumulate in the 
cells treated with PES, as the result of blocking the autophagic flux and the subsequent lack of autophagosome 
clearance [35,36]. The process ends up in a necrotic phenotype with the rupture of the cell membrane [36] . At 
earlier stages we can see the depositions of a proteinaceous material, named aggresomes, which indicates 
damaged proteins in aggregated clumps (Fig. 3B). We can also observe different stages of mitochondrial damage, 
i.e. a variable degree of cristae disruption in swollen mitochondria (Fig. 3B). In conclusion, proteotoxic stress is a 
clear outcome of PES treatment but the downstream mechanisms leading to cell death remain ill-defined. The 
hypothesis about cancer cells being closer to the lethal threshold of proteotoxicity than normal ones provides a 
good explanation for the higher susceptibility of cancer cells to PES. Consistently, we have experimentally 
determined that cells genetically deficient in autophagy are more sensitive to PES (unpublished results). 
Undoubtedly, the deficit in autophagy raises the proteotoxic stress in these cells. 
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Fig. (3). (A) Chemical structure of 2-phenylethynesulfonamide (PES), named also Pifitrin-µ. (B) Transmission 
electron microscopy of HCT116 cells treated for 48 hours with PES (25 µM). Nuclear chromatin (Nu). 
Mitochondria at successive stages of cristae disruption (m). Deposits of proteinaceous material in the cytoplasm 
defined as aggresomes (delimited by arrowheads). (C) HCT116 cells were treated as indicated in the graph with 
PES, the antioxidant N-acetylcysteine (NAC) or the combination of both for 1 hour. ROS detection by means of 
the DCF-DA reagent was performed. Cells were incubated with DCF-DA, treated afterwards and flow cytometry 
was finally used to quantify the percentage of cells that were fluorescent by containing the oxidised DFC. The 
bar values are the mean ± SEM of several independent determinations. 
 
The cellular effects of PES were consistent with an early induction of ROS, which was reversed by a 
reducing agent like N-acetylcysteine (Fig. 3C). This reversion translated into an increased cell survival at longer 
times of treatment [36]. The quantification of intracellular ROS is routinely performed by the reagent 
2’,7’dichlorofluorescin diacetate (DCF-DA). The compound enters the cells and is processed to DCF by the 
intracellular esterases, thus becoming captured inside the cell. Then DFC fluoresces upon oxidation and in 
proportion to the amount of intracellular ROS. In conclusion, a remarkable oxidative stress was involved in the 
mode of action of PES. This fact is important because ROS react with proteins and cause proteotoxic stress. The 
relative amount of proteotoxicity caused by ROS or, alternatively, by HSP70 inhibition in a cell treated with PES 
is unknown and not easy to discern. The concentrations of PES required to inhibit HSP70 in vitro are higher than 
those required in vivo. Therefore, the molecular details of HSP70 inhibition by PES remain unclear [37]. The 
early rise of ROS supports our speculation about a role for PES-triggered oxidative stress in HSP70 inhibition in 
vivo. In addition we have demonstrated that p53 is involved in the necrotic cell death triggered by PES [36]. 
Moreover, we conclude that a positive feed-back between ROS and p53 is leading the cells to their demise. 
BSO (L-buthionine-sulfoximine) is a small molecule with an amino acid structure (Fig. 4A). BSO is a 
pharmacological inhibitor of the enzyme GCL and, therefore, it is able to block the synthesis of GSH in the cells. 
As a consequence, the cells loose their reduction potential and become more susceptible to oxidative stress. The 
combination of PES and BSO potentiates the generation of ROS (Fig. 4B). The combination of PES and BSO is 
synergic at inducing death in several cell lines [36]. This synergism provides another evidence of the involvement 
of ROS in the PES mode of action. Furthermore, it suggests a therapeutic opportunity. BSO is characterized by 
being minimally toxic for cells in culture unless other cellular insults coincide. Consistently, in clinical trials, 
BSO shows minimal toxicity for humans [38]. The association of BSO and conventional chemotherapy has been 
investigated in the past. For instance, in ovarian cancer BSO shows synergism with melphalan and cisplatin 
[39,40]. Similarly, in colon and hepatic carcinoma, BSO and azathioprine synergise [41]. In spite of these 
reported synergisms, BSO has still not reached clinical use. The synergism of BSO and PES is promising. It will 
allow the reduction of the doses of PES without reducing the ratios of cell death. Undoubtedly, a reduced dose of 
PES will translate into minimising its side effects. However, many questions remain. Will the tumor selectivity of 
PES be maintained in association with BSO? What are the toxic effects of PES in humans? How severe can these 
side effects be? Notwithstanding these questions, published evidence supports the interest of combining two 
drugs that cause proteotoxic and oxidative stress respectively [42]. 
In our studies on PES, we found the paradoxical result of Bax protein displaying a pro-survival function 
[35]. Bax and Bak are pro-apoptotic members of the Bcl-2 family of proteins. Both proteins are pivotal elements 
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in the MOMP that leads to apoptosis. Bax is known to be involved in the regulation of mitochondrial dynamics, 
i.e. the state of fusion or fission of mitochondria [43]. This fact prompted us to explore this issue. As a tool we 
used the compound Mdivi-1, which promotes mitochondrial fusion. Mdivi-1 is an inhibitor of the GTPase 
activity of DRP-1, the protein in charge of the mitochondrial fission process [44]. We found that mitochondrial 
fusion had a protective effect in cells treated with PES [35]. It is known that mitochondria respond to oxidative 
stress by fusion. Mitochondrial fusion is interpreted as a mechanism to mix the contents of healthy and damaged 
mitochondria. This allows the compensation of the damaged content, such as oxidised mitochondrial DNA, by 
undamaged one. [45]. Our results are coherent with this explanation since PES was inducing oxidative stress and 
the promotion of mitochondrial fusion was mitigating the toxicity of PES. 
 
Fig. (4). (A) Chemical structure of L-buthionine-sulfoximine (BSO). (B)  U87MG cells were treated as indicated 
in the graph with PES, BSO or the combination of both for 6 hours in 96 multiwell plates. ROS detection was 
performed by the DCF-DA procedure, as before. However, the fluorescence of oxidised DFC was recorded by 
means of a multiwell plate reader. The readings were referred to the untreated condition, which was assigned the 
unit value. The y-axis is expressed as folds over the unit value. The bar value is the mean ± SEM of 5-6 
determinations. 
 
 In conclusion, we envisage ROS as a converging node susceptible of direct (BSO) and probably indirect 
(PES) pharmacology. We have previously commented the positive feed-back between ROS and p53, ROS and 
apoptosis, and ROS and necrosis (Fig. 5). PES illustrates another positive feed-back between proteotoxicity and 
ROS. On one hand, ROS causes chemical modifications, subsequent misfolding and aggregation of proteins. On 
the other hand, proteotoxic stress associated to PES translates into oxidative stress. Moreover, the failure of 
autophagy is also a facet of the PES mode of action. Autophagy is considered a mechanism of cell defence. 
Autophagy alleviates cells from protein aggregates and damaged mitochondria. Finally, mitochondrial dynamics 
adds another dimension to the scheme. Mitochondria fuse to minimise the effects of ROS. However, giant fused 
mitochondria elude autophagy. Apoptosis is associated to mitochondrial fission by stimulating the complete 
proteolysis of the protein OPA-1 and OPA-1 is necessary to accomplish the fusion of the inner mitochondrial 
membrane [45]. Taken these facts altogether, a complex network of interactions is envisaged (Fig. 5). This 
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scheme indicates several targets to be investigated by experimental pharmacologists. In addition, the network 
summarises the mode of action of PES and highlights the involvement of ROS. 
 
 
Fig. (5). Scheme illustrating how ROS are a central node that stablish feed-back positive loops with protetoxic 
stress, p53 and the mechanisms leading to cell death, either apoptotic or necrotic. Mitochondrial outer membrane 
permeabilisation (MOMP) is mediating apoptosis and under regulation by the Bcl-2 family of proteins. Based on 
our results, the participation of autophagy and mitochondrial dynamics (state of mitochondrial fission or fusion) 
has been included in the network of interactions. The existence of drugs targeting these events, like PES, is 
symbolized by thunderbolts. These drugs are potential subjects for experimental pharmacology of cancer. 
Activation is indicated by arrows. Inhibition is depicted as a bar capped line. The dashed line means no 
conclusive evidence. 
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